David Masiello is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 14 publications with 859 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1700 Ceaser E Chavez Ave
Suite 3600
Los Angeles, CA 90033
Telephone
617-320-9510Registry record last updated 22 Dec 2014.
Industry payments
72 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202521 payments
- Janssen Biotech, Inc.Program year202512 payments
- PFIZER INC.Program year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.2%Aromatase Inhibitor22.5%Anastrozole91%Exemestane5%Letrozole4%Part D<11 patientsKinase inhibitor13.4%Calquence23%Imbruvica16%Inlyta14%Jakafi12%Brukinsa11%Everolimus9%Imatinib Mesylate9%Ibrance7%Part D<11 patients+ 17 more classes in this area
Metabolism & gastrointestinal
9.7%Serotonin-3 Receptor Antagonist5.2%Ondansetron Hcl84%Ondansetron Odt16%Part D<11 patientsCorticosteroid2.7%Prednisone100%Part D≥16 patients+ 2 more classes in this area
Sensory organs
5.4%Corticosteroid5.4%Dexamethasone80%Dexamethasone Sodium Phosphate20%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Journal of Hematology & Oncology
2009 - Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study
Journal of Hematology & Oncology
2009
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Andrew Moshfeghi, MD
University of Southern California
Kenneth Nies, MD
University of Southern California
Shuntaro Shinada, MD
University of Southern California
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”